RxDoctor Payments DataLook up a doctor →

Kevin McCarthy, MD

Orthopaedic Surgery · Baton Rouge, LANPI 1407843501

Payments from drug & device makers

$714,231in general payments, 2019–2025

Across 386 payments — averaging $1850.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Precision Spine, Inc.$228K
  • Louisiana United Surgical Services, LLC$141K
  • Providence Medical Technology, Inc.$102K
  • The Institute Of Musculoskeletal Science And Education$79K
  • CTL Medical Corporation$75K
  • Amendia, Inc.$25K
  • plus $66K from 42 others

What the payments were for

  • Royalty or licence$354,25760%
  • Consulting fees$55,9819%
  • Travel & lodging$30,6905%
  • Food & beverage$12,3572%
  • Ownership interest$140,53824%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$714,231 in reported general payments places this provider in the 95th percentile of 286 orthopaedic surgery providers in Louisiana.

See all orthopaedic surgery providers in Louisiana

Medicare billing

Part B allowed, 2024
$201,353
Medicare patients
245
Services billed
3,906

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Piroxicam54$29,846
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,184$15,468
Hysingla ErHydrocodone Bitartrate12$8,115
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen491$7,209
Calcipotriene21$6,684
Xtampza ErOxycodone Myristate11$5,823
Gabapentin311$4,783
Methocarbamol329$2,582
Oxycodone Hcl207$1,579
Tramadol Hcl339$1,551
Pregabalin133$1,427
Cyclobenzaprine Hcl227$1,335
Tizanidine Hcl164$1,119
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine28$696
Meloxicam136$578

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$18$5,82311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 286 orthopaedic surgery providers in Louisiana.

Other orthopaedic surgery in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →